The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Comparison between local and extended field radiotherapy, including regional nodes radiotherapy, in combination with concurrent chemotherapy for T1bN0M0 esophageal cancer.
 
Yukihiro Nakatani
No Relationships to Disclose
 
Ken Kato
Honoraria - Bristol-Myers Squibb Japan; Dainippon Sumitomo Pharma; Lilly; Nippon Kayaku; Pfizer; Sanofi; Taiho Pharmaceutical
Speakers' Bureau - Chugai Pharma; Dainippon Sumitomo Pharma; Eisai; Kyowa Hakko Kirin; Lilly; Merck Serono; MSD; Nippon Kayaku; Novartis; Otsuka; Taiho Pharmaceutical
Research Funding - Merck Serono; MSD; Novartis; Ono Pharmaceutical; Shionogi
 
Hirokazu Shoji
No Relationships to Disclose
 
Satoru Iwasa
Honoraria - Chugai Pharma; Lilly Japan; Taiho Pharmaceutical
 
Yoshitaka Honma
Speakers' Bureau - Nihonkayaku; Novartis; Taiho Pharmaceutical
 
Atsuo Takashima
Speakers' Bureau - Chugai Pharma; Takeda
 
Tetsuya Hamaguchi
Honoraria - Chugai Pharma; Merck Serono; Takeda; Yakult Honsha
Consulting or Advisory Role - NanoCarrier
Research Funding - Daiichi Sankyo (Inst); Dainippon Sumitomo Pharma (Inst); MSD (Inst); NanoCarrier (Inst); Ono Pharmaceutical (Inst); Sanofi (Inst); Taiho Pharmaceutical (Inst); Teijin Pharma (Inst)
 
Yoshinori Ito
No Relationships to Disclose
 
Jun Itami
No Relationships to Disclose
 
Yutaka Saito
No Relationships to Disclose
 
Narikazu Boku
Honoraria - Chugai Pharma; Lilly Japan; Merck Serono; Ono Pharmaceutical; Shionogi; Taiho Pharmaceutical; Takeda; Yakult Honsha
Research Funding - Chugai Pharma (Inst); Taiho Pharmaceutical (Inst)
 
Rei Umezawa
No Relationships to Disclose